Global Biosimilars market, By Recombinant Products (Non-Glycosylated Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood Disorders, Chronic and Auto-immune Disease, infectious diseases and others) opportunities and forecast 2020-2027
Market ScenarioBiosimilars, also known as biologics are the biological products that are manufactured after the patent expiration of the original products. These are presently available for use in oncology and cancer treatment in the supportive care setting. The focus of these drug developments is expected to switch to agents such as monoclonal antibodies in the coming future. These drugs are highly used in the treatment of cancer and the patent expiration of most of the leading drugs and low cost of these products is the major reason propelling the market growth in the current scenario
Low cost of the products, similar efficacy and potency as that of the original products are some of the major reasons driving the growth of the market. Relatively easier manufacturing and the license to manufacture after the expiration of original products are some of the other reasons adding to the market growth. Complex infrastructure needed for the development of these products and legal procedures for the approval are the major factors restricting the market growth. Other factors limiting the market growth includes high cost for the initial setup and legal procedures that restrict new market entries. Increasing cases of various chronic diseases and the patent expiration of most of the drugs is expected to provide new opportunities to the market in the coming years. Also, the improved affordability due to low cost is expected to increase the patient access to most appropriate therapies.
Segment AnalysisGlobal biosimilar market has been segmented majorly on the basis of recombinant products and applications. On the basis of recombinant products the market has been segmented as non-glycosylated proteins, glycosylated proteins, peptides and others. Non-glycosylated recombinant proteins are further divided into insulin, HGH, interferon and others. Further on the basis of application, the market has been segmented as oncology, blood disorders, chronic and autoimmune diseases, infectious diseases and others.
Regional AnalysisGeographically, the market has been segmented into four major economies including North America, Europe, Asia-Pacific, and LAMEA. North America consists of US, Canada, and Mexico. Europe comprises of the major countries including UK, Germany, France, Italy, Spain and Rest of Europe. Similarly, Asia Pacific consists of the major countries such as, Japan, China, India, South Korea, Australia and, Rest of Asia Pacific. LAMEA consists of Brazil, Saudi Arabia, UAE, and Rest of LAMEA.
Key Players
- Pfizer Inc.
- Teva Pharmaceuticals
- Sandoz International GmBH
- Biocon Ltd
- F. Hoffmann-La Roche Ltd.
- Celltrion Inc.
- Amgen
- STADA
- Merck and Co.
- Biogen
Market SegmentationBy Products
- Recombinant Non Glycosylated Proteins
- Insulin
- Human Growth Hormone (HGH)
- Interferon
- Others
- Recombinant Glycosylate Proteins
- Recombinant Peptides
- Others
By Application
- Oncology
- Blood Disorders
- Chronic and Autoimmune Disorders
- Infectious Diseases
- Others
By Geography
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- Rest of LAMEA
